Clinical Trial Update: Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the safety and efficacy of bovine milk immunoglobulin targeting CS17 and CsbD for travelers' diarrhea; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Travelers Diarrhea

Drugs mentioned

• Bovine Milk Immunoglobulin Against CS17 and CsbD (bovine milk immunoglobulin)

Snippet

Sponsor: Johns Hopkins Bloomberg School of Public Health | Conditions: Travelers' Diarrhea | Phase 2 | Status: COMPLETED